SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jalesh N Panicker, Clare J Fowler, Thomas M Kessler, Lower urinary tract dysfunction in the neurological patient: clinical assessment and management, The Lancet Neurology, 2015, 14, 7, 720

    CrossRef

  2. 2
    Areeba Sadiq, Benjamin M. Brucker, Management of Neurogenic Lower Urinary Tract Dysfunction in Multiple Sclerosis Patients, Current Urology Reports, 2015, 16, 7

    CrossRef

  3. 3
    Sachin Malde, Christopher Dowson, Olivia Fraser, Jane Watkins, Muhammed S. Khan, Prokar Dasgupta, Arun Sahai, Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder, BJU International, 2015, 116, 1
  4. 4
    Emmanuel Chartier-Kastler, Eric Rovner, Zsolt Hepp, Kristin Khalaf, Quanhong Ni, Michael Chancellor, Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity, Neurourology and Urodynamics, 2015, 34, 5
  5. 5
    Sheng-Fu Chen, Hann-Chorng Kuo, Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity, Journal of the Formosan Medical Association, 2015, 114, 7, 583

    CrossRef

  6. 6
    Brigitte Schurch, Cécile Tawadros, Stefano Carda, Neurology of Sexual and Bladder Disorders, 2015,

    CrossRef

  7. 7
    Michelle H. Cameron, Francois Bethoux, Nina Davis, Meredith Frederick, Botulinum Toxin for Symptomatic Therapy in Multiple Sclerosis, Current Neurology and Neuroscience Reports, 2014, 14, 8

    CrossRef

  8. 8
    Mark Sanford, OnabotulinumtoxinA (Botox®): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury, Drugs, 2014, 74, 14, 1659

    CrossRef

  9. 9
    Rodney U. Anderson, Elaine K. Orenberg, Patricia Glowe, OnabotulinumtoxinA Office Treatment for Neurogenic Bladder Incontinence in Parkinson's Disease, Urology, 2014, 83, 1, 22

    CrossRef

  10. 10
    Raj Kurpad, Michael J. Kennelly, The Evaluation and Management of Refractory Neurogenic Overactive Bladder, Current Urology Reports, 2014, 15, 10

    CrossRef

  11. 11
    Ulrich Mehnert, Thomas M. Kessler, The management of urinary incontinence in the male neurological patient, Current Opinion in Urology, 2014, 24, 6, 586

    CrossRef

  12. 12
    J. Seth, M. S. Khan, P. Dasgupta, A. Sahai, Botulinum Toxin—What Urologic Uses Does the Data Support?, Current Urology Reports, 2013, 14, 3, 227

    CrossRef

  13. 13
    Antonio Marte, Micaela Borrelli, Maurizio Prezioso, Lucia Pintozzi, Pio Parmeggiani, Efficacy and Safety of Botulinum Toxin A for Treating Bladder Hyperactivity in Children and Adolescents with Neuropathic Bladder Secondary to Myelomeningocele, Dataset Papers in Science, 2013, 2013, 1

    CrossRef

  14. 14
    Ryuji Sakakibara, Masahiko Kishi, Yohei Tsuyusaki, Fuyuki Tateno, Tomoyuki Uchiyama, Tatsuya Yamamoto, Neurology and the bladder: how to assess and manage neurogenic bladder dysfunction. With particular references to neural control of micturition, Rinsho Shinkeigaku, 2013, 53, 3, 181

    CrossRef

  15. 15
    Chung-Cheng Wang, Hann-Chorng Kuo, Satisfaction and quality of life issues in patients receiving urethral botulinum toxin A injections for detrusor sphincter dyssynergia and detrusor botulinum toxin A injections for neurogenic detrusor overactivity, Tzu Chi Medical Journal, 2013, 25, 4, 195

    CrossRef

  16. 16
    Ahmed S. El-Azab, Ahmed M. Moeen, The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty, Arab Journal of Urology, 2013, 11, 4, 344

    CrossRef

  17. 17
    Antonio Marte, Onabotulinumtoxin A for Treating Overactive/Poor Compliant Bladders in Children and Adolescents with Neurogenic Bladder Secondary to Myelomeningocele, Toxins, 2012, 5, 1, 16

    CrossRef